Journal of Hematology & Oncology | |
BCMA-targeted immunotherapy for multiple myeloma | |
Bo Yu1  Delong Liu2  Tianbo Jiang2  | |
[1] Department of Medicine, Lincoln Medical Center, Bronx, NY, USA;Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY, USA; | |
关键词: B cell maturation antigen; BCMA; Belantamab mafodotin; CAR-T; Antibody-drug conjugate; Bispecific T cell engager; | |
DOI : 10.1186/s13045-020-00962-7 | |
来源: Springer | |
【 摘 要 】
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its highly selective expression in malignant plasma cells (PCs). Multiple BCMA-targeted therapeutics, including antibody-drug conjugates (ADC), chimeric antigen receptor (CAR)-T cells, and bispecific T cell engagers (BiTE), have achieved remarkable clinical response in patients with relapsed and refractory MM. Belantamab mafodotin-blmf (GSK2857916), a BCMA-targeted ADC, has just been approved for highly refractory MM. In this article, we summarized the molecular and physiological properties of BCMA as well as BCMA-targeted immunotherapeutic agents in different stages of clinical development.
【 授权许可】
CC BY
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202104244372518ZK.pdf | 1096KB | download |